Lenvatinib dose intensity and tumor response in renal cell carcinoma: considering tumor burden and nephrectomy timing
- 9 November 2026
- journal article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Prognostic impact of lenvatinib dose intensity in previously untreated patients with advanced renal cell carcinoma receiving lenvatinib plus pembrolizumabJapanese Journal of Clinical Oncology, 2026
- Deferred Cytoreductive Nephrectomy in Unresectable/Metastatic Renal Cell Carcinoma: A Real‐World Multicenter Retrospective StudyInternational Journal of Urology, 2026
- Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitorsThe Oncologist, 2025
- Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR StudyEuropean Urology Oncology, 2023
- Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving SunitinibJAMA Oncology, 2019